0 167

Cited 0 times in

Ttreatment results for recurrent glioblastoma and alteration of PD-L1 expression after recurrence

Authors
 Kyoung Su Sung  ;  Tae Hoon Roh  ;  Ju Hyung Moon  ;  Eui Hyun Kim  ;  Seok-Gu Kang  ;  Se Hoon Kim  ;  Jong Hee Chang 
Citation
 WORLD NEUROSURGERY, Vol.135 : e459-e467, 2020 
Journal Title
 WORLD NEUROSURGERY 
ISSN
 1878-8750 
Issue Date
2020
MeSH
B7-H1 Antigen/metabolism* ; Biomarkers/metabolism ; Brain Neoplasms/metabolism ; Brain Neoplasms/mortality ; Brain Neoplasms/surgery* ; Disease-Free Survival ; Female ; Glioblastoma/metabolism ; Glioblastoma/mortality ; Glioblastoma/surgery* ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/surgery* ; Reoperation/statistics & numerical data ; Retrospective Studies ; Treatment Outcome
Keywords
Immune status ; Programmed death-ligand 1 ; Recurrent glioblastoma
Abstract
OBJECTIVE: This study was designed to analyze the results of recurrent glioblastoma (GBM) treatment, investigate the changes in molecular expression on paired primary and recurrent tumor specimens of GBM, and evaluate the effect of these changes on patient survival. METHODS: A total of 170 adult patients were diagnosed with recurrent GBM at a single institution between 2005 and 2015. Patients were divided into the reoperation and nonoperation groups. In addition, we evaluated the expression of immunologic markers of 43 paired surgical specimens from the first and second operations. RESULTS: The median overall survival (OS) after recurrence in the reoperation group was significantly longer than that in the nonoperation group (median, 9.1 months vs. 5.6 months; P = 0.024). The groups differed in characteristics such as age, performance scale, and progression-free survival. In the reoperation group, higher performance scale at recurrence, better extent of resection, and adjuvant treatment were related to longer overall survival. Among 43 paired surgical specimens, programmed death-ligand 1 (PD-L1) was positively expressed in 17 (39.5%) and 6 (13.9%) patients after the first and second operations, respectively. PD-L1 expression after recurrence showed an increase, decrease, and no change in 6 (13.9%), 14 (32.5%), and 23 (53.4%) patients, respectively. Changes in PD-L1 expression after recurrence did not affect survival after recurrence during progression. CONCLUSIONS: The extent of resection and adjuvant treatment was important for prolonged survival. Reoperation without adjuvant treatment was not effective for prolonged survival. Initial and follow-up PD-L1 expression from both operations did not influence patient survival.
Full Text
https://www.sciencedirect.com/science/article/pii/S1878875019330566
DOI
10.1016/j.wneu.2019.12.028
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Gu(강석구) ORCID logo https://orcid.org/0000-0001-5676-2037
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Kim, Eui Hyun(김의현) ORCID logo https://orcid.org/0000-0002-2523-7122
Moon, Ju Hyung(문주형)
Chang, Jong Hee(장종희) ORCID logo https://orcid.org/0000-0003-1509-9800
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/175618
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links